Which rapid acting insulin can be given intravenously (IV)?

The correct choice, Apidra (insulin glulisine), is notable for its formulation, which permits intravenous (IV) administration. This flexibility can be particularly useful in specific clinical situations, such as in a hospital setting where rapid control of blood glucose levels is needed, especially in patients requiring immediate action or who are unable to take insulin via standard routes.

In the context of rapid-acting insulins, while Lispro and Novolog are also rapid-acting insulins, they are primarily administered via subcutaneous injection and are not commonly utilized in IV therapy. Afrezza, as an inhaled insulin, is not suitable for IV administration. This makes Apidra the distinct choice among the options provided due to its compatibility for IV use, highlighting its importance in managing hyperglycemia in various acute care settings.